Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Aligos Therapeutics, Inc. (ALGS) had Return on Tangible Equity of 452.87% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$3.94M |
|
$-131.21M |
|
-- |
|
$3.94M |
|
$93.10M |
|
$-89.15M |
|
$-41.73M |
|
$-130.88M |
|
$-130.88M |
|
$-131.21M |
|
$-131.21M |
|
$-131.21M |
|
$-131.21M |
|
$-89.15M |
|
$-88.31M |
|
6.26M |
|
6.26M |
|
$-20.94 |
|
$-20.94 |
|
| Balance Sheet Financials | |
$62.14M |
|
$2.36M |
|
$7.95M |
|
$70.09M |
|
$21.74M |
|
$0.12M |
|
$77.33M |
|
$99.07M |
|
$-28.97M |
|
$-28.97M |
|
$-28.97M |
|
3.86M |
|
| Cash Flow Statement Financials | |
$-80.74M |
|
$-18.28M |
|
$0.35M |
|
$135.77M |
|
$37.11M |
|
$-98.67M |
|
$8.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.86 |
|
-- |
|
-- |
|
-0.00 |
|
-0.01 |
|
100.00% |
|
-2259.92% |
|
-2259.92% |
|
-2238.66% |
|
-3317.62% |
|
-3326.01% |
|
$-80.87M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
-- |
|
-- |
|
452.87% |
|
|
Return on Tangible Equity |
452.87% |
-187.19% |
|
454.79% |
|
$-7.50 |
|
$-12.91 |
|
$-12.89 |
|